Exosomes derived from miR-188-3p-modified adipose-derived mesenchymal stem cells protect Parkinson’s disease

Li, Qiang; Wang, Zihao; Xing, Hao; Wang, Yu; Guo, Yi

doi:10.1016/j.omtn.2021.01.022

Cited by 91 publications

(77 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the case of Parkinson's disease (PD), it was shown that treatment with miR-188-3p-enriched exosomes suppressed autophagy and pyroptosis. This miRNA targets NACHT domain-containing protein 3 and protein kinase 5 of cell division [250]. Other RNAs that may have therapeutic potential for the treatment of PD are miR-7, whose expression enables normal development, physiology and neurogenesis in the central nervous system, and also maintains alpha-synuclein (α-Syn) at the physiological level [251] and miR-30a-5p, which contributes to the pathogenesis of PD by regulating ubiquitin-mediated degradation of glutamate transporter 1.…”

Section: Potential Role Of Exosomes In the Treatment Of Neurodegenerative Diseasesmentioning

confidence: 99%

Exosomes: Potential Disease Biomarkers and New Therapeutic Targets

et al. 2021

View full text Add to dashboard Cite

Exosomes are extracellular vesicles released by cells, both constitutively and after cell activation, and are present in different types of biological fluid. Exosomes are involved in the pathogenesis of diseases, such as cancer, neurodegenerative diseases, pregnancy disorders and cardiovascular diseases, and have emerged as potential non-invasive biomarkers for the detection, prognosis and therapeutics of a myriad of diseases. In this review, we describe recent advances related to the regulatory mechanisms of exosome biogenesis, release and molecular composition, as well as their role in health and disease, and their potential use as disease biomarkers and therapeutic targets. In addition, the advantages and disadvantages of their main isolation methods, characterization and cargo analysis, as well as the experimental methods used for exosome-mediated drug delivery, are discussed. Finally, we present potential perspectives for the use of exosomes in future clinical practice.

show abstract

Section: Potential Role Of Exosomes In the Treatment Of Neurodegenerative Diseasesmentioning

confidence: 99%

Exosomes: Potential Disease Biomarkers and New Therapeutic Targets

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Xia and colleagues also showed they were involved in the inhibition of autophagy and accumulation of α-synuclein [ 54 ]. Although the origin of EVs in peripheral blood in this study is not clear, EVs are produced by adipose-derived stem cells (ADSCs) [ 55 ] and secreted into the blood [ 56 ].…”

Section: Evs That Are Taken Up By Astrocytes Under Disease Conditionsmentioning

confidence: 99%

Extracellular Vesicles Taken up by Astrocytes

Ogaki

Ikegaya

Koyama

2021

IJMS

View full text Add to dashboard Cite

Extracellular vesicles (EVs) are composed of lipid bilayer membranes and contain various molecules, such as mRNA and microRNA (miRNA), that regulate the functions of the recipient cell. Recent studies have reported the importance of EV-mediated intercellular communication in the brain. The brain contains several types of cells, including neurons and glial cells. Among them, astrocytes are the most abundant glial cells in the mammalian brain and play a wide range of roles, from structural maintenance of the brain to regulation of neurotransmission. Furthermore, since astrocytes can take up EVs, it is possible that EVs originating from inside and outside the brain affect astrocyte function, which in turn affects brain function. However, it has not been fully clarified whether the specific targeting mechanism of EVs to astrocytes as recipient cells exists. In recent years, EVs have attracted attention as a cell-targeted therapeutic approach in various organs, and elucidation of the targeting mechanism of EVs to astrocytes may pave the way for new therapies for brain diseases. In this review, we focus on EVs in the brain that affect astrocyte function and discuss the targeting mechanism of EVs to astrocytes.

show abstract

“…Their beneficial therapeutic effects reduced loss of dopamine neurons with concomitant amelioration of the motor deficits in the 6-hydroxydopamine PD animal model. [71][72][73][74]…”

Section: Dovepressmentioning

confidence: 99%

View Point: Disease Modification and Cell Secretome Based Approaches in Parkinson’s Disease: Are We on the Right Track?

Müller¹

2021

BTT

View full text Add to dashboard Cite

The term idiopathic Parkinson’s disease describes an entity of various not well-characterized disorders resembling each other. They are characterized by chronic neuronal dying originating from various disease mechanisms. They result in the onset of motor and related non-motor features, both of which respond to administration of personalized drug combinations and surgical therapies. The unmet need is beneficial disease course modification with repair and neurogenesis. Objectives are to discuss the value of cell secretome based treatments including neuronal graft transplantation and to suggest as an alternative the stimulation of an endogenous available approach for neuronal repair. Chronic neurodegenerative processes result from different heterogeneous, but complementing metabolic, pathological cascade sequences. Accumulated evidence from experimental research suggested neuron transplantation, stem cell application and cell secretome-based therapies as a promising future treatment with cure as an ultimate goal. To date, clinical testing of disease-modifying treatments has focused on substitution or repair of the remaining dopamine synthesizing neurons following diagnosis. At diagnosis, many of the still surviving and functioning, but already affected neurons have lost most of their axons and are primed for cell death. A more promising therapeutic concept may be the stimulation of an existing, endogenous repair system in the peripheral and central nervous systems. The abundant protein repulsive guidance molecule A blocks restoration and neurogenesis, both of which are mediated via the neogenin receptor. Inhibition of the physiological effects of repulsive guidance molecule A is an endogenous available repair pathway in chronic neurodegeneration. Antagonism of this protein with antibodies or stimulation of the neogenin receptor should be considered as an initial repair step. It is an alternative to cell replacement, stem cell or associated cell secretome concepts.

show abstract

Exosomes derived from miR-188-3p-modified adipose-derived mesenchymal stem cells protect Parkinson’s disease

Cited by 91 publications

References 31 publications

Exosomes: Potential Disease Biomarkers and New Therapeutic Targets

Exosomes: Potential Disease Biomarkers and New Therapeutic Targets

Extracellular Vesicles Taken up by Astrocytes

View Point: Disease Modification and Cell Secretome Based Approaches in Parkinson’s Disease: Are We on the Right Track?

Contact Info

Product

Resources

About